Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 29 | 2024 | 5097 | 1.960 |
Why?
|
| Anti-HIV Agents | 16 | 2024 | 1324 | 1.460 |
Why?
|
| Benzoxazines | 2 | 2024 | 123 | 1.040 |
Why?
|
| Anti-Retroviral Agents | 10 | 2023 | 551 | 0.940 |
Why?
|
| Alkynes | 2 | 2024 | 117 | 0.930 |
Why?
|
| Cyclopropanes | 2 | 2024 | 123 | 0.930 |
Why?
|
| Oxazines | 1 | 2024 | 81 | 0.870 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2024 | 85 | 0.870 |
Why?
|
| Weight Gain | 1 | 2024 | 77 | 0.860 |
Why?
|
| Pyridones | 1 | 2024 | 100 | 0.860 |
Why?
|
| Coinfection | 2 | 2024 | 276 | 0.850 |
Why?
|
| Humans | 35 | 2025 | 14537 | 0.640 |
Why?
|
| Female | 29 | 2025 | 9103 | 0.630 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2019 | 472 | 0.600 |
Why?
|
| Child | 20 | 2022 | 2242 | 0.560 |
Why?
|
| South Africa | 18 | 2025 | 7596 | 0.560 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2018 | 324 | 0.520 |
Why?
|
| Child, Preschool | 17 | 2021 | 1748 | 0.500 |
Why?
|
| Male | 22 | 2024 | 6754 | 0.490 |
Why?
|
| Seroepidemiologic Studies | 2 | 2024 | 109 | 0.420 |
Why?
|
| Antitubercular Agents | 4 | 2018 | 322 | 0.420 |
Why?
|
| Adolescent | 17 | 2025 | 2985 | 0.420 |
Why?
|
| Adult | 8 | 2025 | 5913 | 0.410 |
Why?
|
| Infant | 14 | 2021 | 2244 | 0.390 |
Why?
|
| Lamivudine | 2 | 2024 | 89 | 0.370 |
Why?
|
| Retrospective Studies | 6 | 2025 | 799 | 0.360 |
Why?
|
| Tuberculosis | 4 | 2015 | 543 | 0.320 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2023 | 187 | 0.310 |
Why?
|
| Infant, Newborn | 8 | 2024 | 1479 | 0.300 |
Why?
|
| Ambulatory Care | 2 | 2018 | 54 | 0.300 |
Why?
|
| Prospective Studies | 5 | 2024 | 1160 | 0.280 |
Why?
|
| Pregnancy | 5 | 2025 | 1862 | 0.280 |
Why?
|
| Time Factors | 5 | 2019 | 507 | 0.270 |
Why?
|
| Longitudinal Studies | 3 | 2024 | 435 | 0.270 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2018 | 656 | 0.250 |
Why?
|
| Tetanus Toxoid | 1 | 2025 | 14 | 0.240 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2015 | 33 | 0.240 |
Why?
|
| Climate Change | 1 | 2024 | 27 | 0.230 |
Why?
|
| Emtricitabine | 1 | 2024 | 78 | 0.220 |
Why?
|
| Maternal Death | 1 | 2024 | 25 | 0.220 |
Why?
|
| Piperazines | 1 | 2024 | 82 | 0.220 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 38 | 0.210 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 370 | 0.210 |
Why?
|
| Africa, Southern | 5 | 2022 | 91 | 0.210 |
Why?
|
| Tenofovir | 1 | 2024 | 171 | 0.210 |
Why?
|
| Influenza Vaccines | 1 | 2025 | 144 | 0.210 |
Why?
|
| Reproductive Health Services | 1 | 2023 | 66 | 0.210 |
Why?
|
| Vaccination | 1 | 2025 | 365 | 0.200 |
Why?
|
| Vaccines | 1 | 2024 | 86 | 0.200 |
Why?
|
| Body Mass Index | 1 | 2024 | 321 | 0.200 |
Why?
|
| Pregnant Women | 1 | 2022 | 89 | 0.200 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 1422 | 0.200 |
Why?
|
| Prevalence | 2 | 2022 | 1192 | 0.190 |
Why?
|
| Cohort Studies | 7 | 2019 | 967 | 0.190 |
Why?
|
| Patient Compliance | 2 | 2018 | 120 | 0.180 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 51 | 0.180 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2023 | 196 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 284 | 0.180 |
Why?
|
| Middle Aged | 3 | 2024 | 3601 | 0.180 |
Why?
|
| Global Health | 2 | 2019 | 193 | 0.180 |
Why?
|
| Asymptomatic Infections | 1 | 2020 | 34 | 0.170 |
Why?
|
| Lopinavir | 3 | 2015 | 137 | 0.170 |
Why?
|
| Viral Load | 6 | 2023 | 819 | 0.170 |
Why?
|
| Mass Screening | 2 | 2020 | 245 | 0.170 |
Why?
|
| Ritonavir | 3 | 2015 | 137 | 0.170 |
Why?
|
| Primary Health Care | 2 | 2019 | 240 | 0.170 |
Why?
|
| Mental Health | 1 | 2020 | 91 | 0.170 |
Why?
|
| Sentinel Surveillance | 1 | 2020 | 115 | 0.170 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2025 | 529 | 0.170 |
Why?
|
| Growth Disorders | 1 | 2019 | 56 | 0.160 |
Why?
|
| Colposcopy | 1 | 2019 | 17 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2019 | 33 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.160 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2019 | 36 | 0.160 |
Why?
|
| Disease Management | 1 | 2019 | 74 | 0.160 |
Why?
|
| World Health Organization | 1 | 2018 | 137 | 0.150 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 74 | 0.150 |
Why?
|
| Lost to Follow-Up | 1 | 2018 | 62 | 0.150 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 39 | 0.150 |
Why?
|
| Isoniazid | 1 | 2018 | 110 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 127 | 0.150 |
Why?
|
| Young Adult | 5 | 2025 | 2498 | 0.150 |
Why?
|
| HIV Protease Inhibitors | 2 | 2015 | 92 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 115 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 256 | 0.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2020 | 472 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 280 | 0.130 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 7 | 0.130 |
Why?
|
| Sarcoma, Kaposi | 1 | 2016 | 53 | 0.130 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 163 | 0.130 |
Why?
|
| Child Development | 1 | 2016 | 93 | 0.120 |
Why?
|
| Rifabutin | 1 | 2014 | 4 | 0.120 |
Why?
|
| Neoplasms | 1 | 2016 | 147 | 0.120 |
Why?
|
| HIV-1 | 2 | 2020 | 1260 | 0.110 |
Why?
|
| Incidence | 4 | 2018 | 685 | 0.110 |
Why?
|
| Treatment Failure | 3 | 2019 | 175 | 0.110 |
Why?
|
| Drug Resistance, Viral | 1 | 2015 | 278 | 0.100 |
Why?
|
| Asia | 3 | 2018 | 72 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2018 | 889 | 0.100 |
Why?
|
| Developmental Disabilities | 1 | 2012 | 22 | 0.100 |
Why?
|
| Prenatal Care | 2 | 2025 | 147 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2022 | 64 | 0.080 |
Why?
|
| Risk Factors | 3 | 2020 | 1475 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2018 | 149 | 0.080 |
Why?
|
| Europe | 2 | 2017 | 56 | 0.070 |
Why?
|
| Africa | 2 | 2018 | 376 | 0.060 |
Why?
|
| Vaccination Coverage | 1 | 2025 | 13 | 0.060 |
Why?
|
| Tetanus | 1 | 2025 | 10 | 0.060 |
Why?
|
| Africa South of the Sahara | 2 | 2016 | 353 | 0.060 |
Why?
|
| Immunization Schedule | 1 | 2025 | 81 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 279 | 0.060 |
Why?
|
| Health Policy | 1 | 2024 | 140 | 0.050 |
Why?
|
| Stillbirth | 1 | 2024 | 83 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2023 | 85 | 0.050 |
Why?
|
| Point-of-Care Testing | 1 | 2023 | 71 | 0.050 |
Why?
|
| Influenza, Human | 1 | 2025 | 374 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 80 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.040 |
Why?
|
| Research | 1 | 2020 | 65 | 0.040 |
Why?
|
| Adolescent Development | 1 | 2019 | 13 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 56 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2019 | 43 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 370 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2019 | 9 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 125 | 0.040 |
Why?
|
| Papanicolaou Test | 1 | 2019 | 29 | 0.040 |
Why?
|
| Vaginal Smears | 1 | 2019 | 34 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 80 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 36 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 156 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 296 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 154 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 45 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 50 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2018 | 118 | 0.040 |
Why?
|
| Africa, Western | 1 | 2017 | 8 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 22 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2017 | 89 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 107 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 105 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 111 | 0.030 |
Why?
|
| Togo | 1 | 2016 | 1 | 0.030 |
Why?
|
| Senegal | 1 | 2016 | 3 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cote d'Ivoire | 1 | 2016 | 6 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 42 | 0.030 |
Why?
|
| Burkina Faso | 1 | 2016 | 29 | 0.030 |
Why?
|
| Ghana | 1 | 2016 | 67 | 0.030 |
Why?
|
| Malawi | 1 | 2016 | 87 | 0.030 |
Why?
|
| Zimbabwe | 1 | 2016 | 120 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 225 | 0.030 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2015 | 8 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 65 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 20 | 0.030 |
Why?
|
| Latin America | 1 | 2014 | 10 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 104 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2014 | 303 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 442 | 0.030 |
Why?
|
| Nervous System | 1 | 2012 | 3 | 0.020 |
Why?
|
| HIV | 1 | 2015 | 380 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 12 | 0.020 |
Why?
|
| AIDS Dementia Complex | 1 | 2012 | 29 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 55 | 0.020 |
Why?
|
| Malnutrition | 1 | 2012 | 56 | 0.020 |
Why?
|
| Poverty | 1 | 2012 | 152 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 480 | 0.020 |
Why?
|